The American Journal of Medicine
Volume 121, Issue 10 , Pages 876-884 , October 2008

Emergence of Fluoroquinolone Resistance in Outpatient Urinary Escherichia coli Isolates

Presented in part at the 30th annual meeting of the Society of General Internal Medicine in Toronto, Canada, on April 26, 2007.

  • Luke Johnson

      Affiliations

    • University of Denver and Department of Patient Safety and Quality, Denver Health and Hospital Authority, Denver, Colo
    • ,
  • Allison Sabel, MD, PhD, MPH, CMQ

      Affiliations

    • Department of Patient Safety and Quality, Denver Health and Hospital Authority and Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver, Colo
    • ,
  • William J. Burman, MD

      Affiliations

    • Denver Public Health Department and Department of Medicine, Divisions of Infectious Diseases, Denver Health and Hospital Authority and University of Colorado Health Sciences Center, Denver, Colo
    • ,
  • Rachel M. Everhart, MS

      Affiliations

    • Department of Patient Safety and Quality, Denver Health and Hospital Authority, Denver, Colo
    • ,
  • Marcie Rome

      Affiliations

    • Amherst College, Amherst, Mass, and Department of Medicine, Divisions of Infectious Diseases, Denver Health and Hospital Authority, Denver, Colo
    • ,
  • Thomas D. MacKenzie, MD, MSPH

      Affiliations

    • Denver Community Health Services and Department of Patient Safety and Quality, Denver Health and Hospital Authority and Department of Medicine, Division of General Internal Medicine, University of Colorado Health Sciences Center, Denver, Colo
    • ,
  • Jeanne Rozwadowski, MD

      Affiliations

    • Denver Community Health Services, Denver Health and Hospital Authority Department of Medicine, Division of General Internal Medicine, University of Colorado Health Sciences Center, Denver, Colo
    • ,
  • Philip S. Mehler, MD

      Affiliations

    • Department of Patient Safety and Quality, Denver Health and Hospital Authority and Department of Medicine, Division of General Internal Medicine, University of Colorado Health Sciences Center, Denver, Colo
    • ,
  • Connie Savor Price, MD

      Affiliations

    • Department of Medicine, Divisions of Infectious Diseases, Denver Health and Hospital and Authority and University of Colorado Health Sciences Center, Denver, Colo
    • Corresponding Author InformationRequests for reprints should be addressed to Connie Savor Price, MD, 777 Bannock Street, MC 4000, Denver, CO 80204

References 

  1. Burt CW, Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1999–2000. Vital Health Stat 13. 2004;1–70
  2. Burman WJ, Breese PE, Murray BE, et al. Conventional and molecular epidemiology of trimethoprim-sulfamethoxazole resistance among urinary Escherichia coli isolates. Am J Med. 2003;115:358–364
  3. Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women (Infectious Diseases Society of America (IDSA)). Clin Infect Dis. 1999;29:745–758
  4. Gabow P, Eisert S, Wright R. Denver Health: a model for the integration of a public hospital and community health centers. Ann Intern Med. 2003;138:143–149
  5. Clancy MJ, Graepler A, Breese PE, et al. Widespread emergence of methicillin resistance in community-acquired Staphylococcus aureus infections in Denver. South Med J. 2005;98:1069–1075
  6. Clinical Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. 6th ed.. Wayne, PA: Clinical and Laboratory Standards Institute; 2003;approved standard M7-A6
  7. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: Clinical and Laboratory Standards Institute; 2005;Vol 15 informational supplement M100-S15
  8. Taur Y, Smith MA. Adherence to the Infectious Diseases Society of America guidelines in the treatment of uncomplicated urinary tract infection. Clin Infect Dis. 2007;44:769–774
  9. Grover ML, Bracamonte JD, Kanodia AK, et al. Assessing adherence to evidence-based guidelines for the diagnosis and management of uncomplicated urinary tract infection. Mayo Clin Proc. 2007;82:181–185
  10. Kallen AJ, Welch HG, Sirovich BE. Current antibiotic therapy for isolated urinary tract infections in women. Arch Intern Med. 2006;166:635–639
  11. Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents. 2006;27:468–475
  12. Kahan NR, Chinitz DP, Waitman DA, et al. Empiric treatment of uncomplicated urinary tract infection with fluoroquinolones in older women in Israel: another lost treatment option?. Ann Pharmacother. 2006;40:2223–2227
  13. Cohen AE, Lautenbach E, Morales KH, Linkin DR. Fluoroquinolone-resistant Escherichia coli in the long-term care setting. Am J Med. 2006;119:958–963
  14. Arslan H, Azap OK, Ergonul O, Timurkaynak F. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother. 2005;56:914–918
  15. Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother. 2004;38:1148–1152
  16. Ena J, Amador C, Martinez C, Ortiz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol. 1995;153:117–120
  17. Furuno JP, McGregor JC, Harris AD, et al. Identifying groups at high risk for carriage of antibiotic-resistant bacteria. Arch Intern Med. 2006;166:580–585
  18. Ortiz J, Vila MC, Soriano G, et al. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology. 1999;29:1064–1069
  19. Sotto A, De Boever CM, Fabbro-Peray P, et al. Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study. J Clin Microbiol. 2001;39:438–444
  20. Jellen-Ritter AS, Kern WV. Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants selected with a fluoroquinolone. Antimicrob Agents Chemother. 2001;45:1467–1472
  21. Alekshun MN, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. Cell. 2007;128:1037–1050
  22. Conklin JD. The pharmacokinetics of nitrofurantoin and its related bioavailability. Antibiot Chemother. 1978;25:233–252
  23. Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med. 2007;167:2207-2012
  24. Hooton TM, Winter C, Tiu F, Stamm WE. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA. 1995;273:41–45
  25. Hooton TM, Besser R, Foxman B, et al. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis. 2004;39:75–80
  26. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med. 2002;113(Suppl 1A):14S–19S

 Financial Disclosures: none.

PII: S0002-9343(08)00606-2

doi: 10.1016/j.amjmed.2008.04.039

The American Journal of Medicine
Volume 121, Issue 10 , Pages 876-884 , October 2008

Article Tools

* Image Usage & Resolution